Glucagon-like peptide-1: difference between revisions
Diff·revision 19 → 20·01:13, 8 Mar 2025
Difference between revision 19 and revision 20 of Glucagon-like peptide-1. 2 lines changed; the page grew by 47 bytes.
| Revision 19 — 09:25, 16 Feb 2025 DPP4_Dagmar (talk) add the counter-regulatory glucagon point, sourced 10,192 bytes +175 | Revision 20 — 01:13, 8 Mar 2025 ScopeSeverin (talk) split §Physiology from §Pharmacological exploitation 10,239 bytes +47 | ||
|---|---|---|---|
| 71 | Actions on the heart, kidney, liver and immune system have all been described, and cardiovascular and renal benefit has been demonstrated for several agonists in outcome trials; the extent to which those benefits are receptor-mediated rather than secondary to weight and glycaemic change remains an open question.{{r|drucker2018}} | 71 | Actions on the heart, kidney, liver and immune system have all been described, and cardiovascular and renal benefit has been demonstrated for several agonists in outcome trials; the extent to which those benefits are receptor-mediated rather than secondary to weight and glycaemic change remains an open question.{{r|drucker2018}} |
| 72 | 72 | ||
| + | 73 | {{seealso|GLP-1 receptor|Beta cell function}} | |
| + | 74 | ||
| 73 | == References == | 75 | == References == |
| 74 | {{reflist}} | 76 | {{reflist}} |